Publication:
Anticancer potential of albumin bound wnt/β-catenin pathway inhibitor niclosamide in breast cancer cells

dc.contributor.authorAri, Ferda
dc.contributor.authorErkisa, Merve
dc.contributor.authorPekel, Gonca
dc.contributor.authorBuyukkoroglu, Gulay
dc.contributor.authorUlukaya, Engin
dc.contributor.buuauthorErturk, Elif
dc.contributor.buuauthorERTÜRK, ELİF
dc.contributor.buuauthorArı, Ferda
dc.contributor.buuauthorErkısa, Merve
dc.contributor.departmentBursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü.
dc.contributor.departmentBursa Uludağ Üniversitesi/Sağlık Hizmetleri Meslek Yüksekokulu.
dc.contributor.orcid0000-0002-6729-7908
dc.contributor.orcid0000-0002-3127-742X
dc.contributor.orcid0000-0002-5089-6007
dc.contributor.orcid0000-0003-4875-5472
dc.contributor.researcheridK-5792-2018
dc.contributor.researcheridN-6551-2019
dc.contributor.researcheridJQI-3400-2023
dc.contributor.researcheridAAM-1001-2020
dc.contributor.researcheridIWM-5784-2023
dc.date.accessioned2024-06-26T11:22:00Z
dc.date.available2024-06-26T11:22:00Z
dc.date.issued2021-08-06
dc.description.abstractAlbumin-based nanoparticle transport systems (nab-technology) are a new strategy in cancer treatment and we aimed to increase the effectiveness of Niclosamide using this technology. Niclosamide was bound with bovine serum albumin (BSA) by desolvation to yield nanoparticle albumin-bound Niclosamide (nab-Niclo). Nab-Niclo anticancer activity was assessed by proliferation, apoptosis and DNA damage analyses on breast cancer cells. The results implied that nab-Niclo was a more potent agent in the inhibition of cell viability than free Niclosamide and albumin. Flow cytometry analysis show that nab-Niclo triggered apoptosis by caspase and mitochondriadependent pathways in cells and nab-Niclo enhances apoptosis by induce DNA damage in cells. Overall results of this study showed that the nanoparticle form of Niclosamide is effective for breast cancer treatment, presenting a new treatment strategy that can be safe and effective for breast cancer patients.
dc.identifier.doi10.1002/slct.202100819
dc.identifier.endpage7475
dc.identifier.issn2365-6549
dc.identifier.issue29
dc.identifier.startpage7463
dc.identifier.urihttps://doi.org/10.1002/slct.202100819
dc.identifier.urihttps://hdl.handle.net/11452/42437
dc.identifier.volume6
dc.identifier.wos000765993600005
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherWiley-v C H Verlag Gmbh
dc.relation.journalChemistryselect
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDrug-delivery system
dc.subjectGelatin nanoparticles
dc.subjectOptimization
dc.subjectAlbumin
dc.subjectApoptosis
dc.subjectBreast cancer
dc.subjectNanoparticles
dc.subjectNiclosamide
dc.subjectScience & technology
dc.subjectPhysical sciences
dc.subjectChemistry, multidisciplinary
dc.subjectChemistry
dc.titleAnticancer potential of albumin bound wnt/β-catenin pathway inhibitor niclosamide in breast cancer cells
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication54fbb8ee-6806-4d77-9430-9b360d81a2ab
relation.isAuthorOfPublication.latestForDiscovery54fbb8ee-6806-4d77-9430-9b360d81a2ab

Files

Collections